Hair cloning is not yet available as a commercial treatment, and no company has completed human clinical trials. The most advanced efforts are still in pre-clinical stages, meaning the technology has been tested in lab animals but not yet proven safe and effective in people. A realistic timeline for a widely available treatment is likely a decade or more away, though several companies are making measurable progress.
Why Hair Cloning Is So Difficult
The core idea behind hair cloning sounds straightforward: take a small number of your own hair-producing cells, multiply them in a lab, and inject or implant them back into your scalp to grow new hair. The problem is that the key cells responsible for triggering hair growth, found in a tiny structure at the base of each follicle called the dermal papilla, quickly lose their ability to produce hair once they’re removed from the body and grown in a dish.
Researchers have known about this problem for decades. When these cells are spread flat in a standard lab culture, they lose their molecular identity within just a few rounds of division. They stop behaving like hair-forming cells and start acting like generic skin cells. This happens because the cells depend on a complex set of signals from neighboring tissues inside a living follicle, signals that vanish in a flat petri dish. Without those cues, the cells essentially forget what they are.
Several workarounds have shown promise in animal studies. Growing dermal papilla cells in three-dimensional clusters instead of flat layers helps them retain their hair-forming properties longer. Co-culturing them with skin cells or adding specific signaling proteins (from the Wnt and BMP families) can also preserve their function through many more rounds of division. In one experiment, rat dermal papilla cells maintained their hair-growing ability through 70 rounds of replication when cultured alongside skin cells. But translating these results from rodent whisker follicles to adult human scalp hair has proven far more difficult, and no group has achieved consistent, large-scale human hair follicle generation from adult patient cells.
Where the Leading Companies Stand
Stemson Therapeutics, founded in 2018, is the most frequently cited company in this space. Stemson uses induced pluripotent stem cells, which are adult cells reprogrammed back to a flexible state, to create hair follicle components. The company announced a breakthrough after successfully growing human hair follicles in mice with humanized skin. That result moved them into what they describe as “final stages of product development” before human clinical trials, but no trial start date has been publicly confirmed. The company is integrating machine learning to improve the consistency and reproducibility of their approach, which hints at how variable the results still are.
Shiseido, the Japanese cosmetics giant, licensed a technology called RCH-01 that takes a different approach. Instead of creating entirely new follicles, it involves extracting a patient’s own dermal papilla cells, culturing them, and re-injecting them to rejuvenate miniaturized (thinning) follicles. A Phase 1 trial validated basic safety in humans, and Shiseido built a dedicated cell-processing facility in Japan. But the company has been quiet about efficacy data and timelines in recent years, which suggests the results may not have been as strong as hoped.
HairClone, a UK-based company, is taking a more cautious, long-term approach. Rather than offering treatment now, they allow patients to bank whole hair follicles through partner clinics. The follicles are cryopreserved at minus 180 degrees Celsius and can be stored for 20 to 25 years, with annual maintenance fees of roughly £150. The idea is that patients preserve their healthiest follicles today so they’ll have viable cells available when cloning technology matures. It’s a bet on the future, not a current solution.
Meanwhile, a German company called TissUse has published research on growing simplified “microfollicles” inside organ-on-a-chip systems, tiny devices that simulate the conditions inside a living body. Their work has demonstrated early signs of hair follicle formation in reconstructed human skin, including the structural inward growth that precedes real hair production. But this research is primarily aimed at drug testing and basic science, not direct patient treatment.
New Tools That Could Accelerate Progress
One of the more promising recent developments involves 3D-printed scaffolds designed to give lab-grown follicle cells the physical structure they need. A 2025 study created a biodegradable scaffold from alginate and gelatin that allowed clusters of hair follicle cells to mature inside engineered skin. The scaffolds had controllable pore sizes and degradation rates, and the follicle cells grown within them expressed key markers of real hair follicles. This is still an in vitro result, not a treatment, but it represents a meaningful step toward building follicles outside the body with enough structural integrity to function.
The broader shift in the field is toward recreating the follicle’s natural environment rather than just multiplying cells. Researchers are combining 3D culture systems, signaling molecules, bioengineered scaffolds, and stem cell reprogramming to try to solve the problem from multiple angles simultaneously. Each of these approaches has shown partial success, but nobody has put all the pieces together into a reliable, scalable system for human use.
The Cosmetic Challenge Beyond Biology
Even if scientists solve the cell biology, there’s a separate set of problems related to making cloned hair look natural. Hair transplant surgeons already struggle with this in conventional procedures. The angle, direction, curl, and thickness of each hair shaft all affect appearance, and getting them wrong creates an obviously artificial look.
Transplanted hair doesn’t always follow the angle it’s implanted at. Curly or wavy hair grows according to its own curl pattern after it exits the skin, regardless of how the follicle was positioned. Thick donor hairs placed in areas where the natural hair is thin can project outward instead of lying flat, creating a stark mismatch. These issues are manageable in skilled hands with conventional transplants, but they become far more complex when you’re implanting thousands of lab-grown follicles that may not perfectly match the patient’s native hair in texture or caliber.
Realistic Timeline and Expected Cost
Based on where the science stands today, a commercially available hair cloning treatment is unlikely before the early-to-mid 2030s at the earliest. The most advanced companies still need to begin and complete human clinical trials, which typically take several years across multiple phases. Regulatory approval adds additional time. And scaling up a cell therapy from a lab protocol to a product that can be reliably delivered in thousands of clinics worldwide is its own multi-year challenge.
Cost projections are speculative, but current stem cell hair treatments (which are less advanced than true cloning) range from $2,000 to $30,000 per session. A fully developed hair cloning procedure would likely fall somewhere in that range initially, possibly at the higher end given the complexity of cell processing. For comparison, conventional hair transplants using existing methods typically cost $3,000 to $15,000 depending on the number of grafts and clinic location. Over time, as techniques standardize and competition increases, prices would be expected to drop.
If you’re experiencing hair loss now, current options like conventional transplants and medical therapies remain the most proven approaches. Banking follicles through services like HairClone is a reasonable hedge if you want to preserve your options, but it’s a gamble on a technology that doesn’t exist yet in clinical form. The science is advancing, but the gap between growing hair on a mouse and offering a reliable treatment to millions of people remains substantial.